Lecithin cholesterol acyltransferase: An anti- or pro-atherogenic factor?

Current Atherosclerosis Reports

Volumn 13, Issue 3, 2011, Pages 249-256

  Rousset, Xavier ^a   Shamburek, Robert ^a   Vaisman, Boris ^a   Amar, Marcelo ^a   Remaley, Alan T ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Atherosclerosis; Biomarker; Cholesterol; Enzyme replacement therapy; Fish eye disease; High density lipoprotein; Lecithin cholesterol acyltransferase; Reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; AGENTS AFFECTING LIPID METABOLISM; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; RECOMBINANT LECITHIN CHOLESTEROL ACYLTRANSFERASE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HUMAN; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; LIPOPROTEIN METABOLISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA TRANSFUSION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FATTY ACIDS; HUMANS; LECITHIN ACYLTRANSFERASE DEFICIENCY; LIPID METABOLISM; MICE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; RABBITS; SAIMIRI;

EID: 79955880471     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-011-0171-6     Document Type: Review

References (51)

1. Rousset X, Vaisman B, Amar M, Sethi AA, Remaley AT. Lecithin: cholesterol acyltransferase - from biochemistry to role in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2009;16(2):163-71.
2. Santamarina-Fojo S, Hoeg JM, Assmann G, H. Bryan Brewer J: Lecithin Cholesterol Acyltransferase Deficiency and Fish Eye Disease. In: Metabolic & Molecular Bases of Inherited Disease. 2001.
3. Chang T-Y, Li B-L, Chang CCY, Urano Y. Acyl-coenzyme A: cholesterol acyltransferases. Am J Physiol Endocrinol Metab. 2009;297(1):E1-9.
4. Czarnecka H, Yokoyama S. Regulation of cellular cholesterol efflux by lecithin:cholesterol acyltransferase reaction through nonspecific lipid exchange. Journal of Biological Chemistry. 1996;271(4):2023-8. (Pubitemid 26047786)
5. Nofer JR, Remaley A. Tangier disease: still more questions than answers. Cellular and Molecular Life Sciences. 2005;62(19):2150-60. (Pubitemid 41500535)
6. Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscl Throm Vas. 2010;30(7):1430-U1405.
7. Nishiwaki M, Ikewaki K, Bader G, et al. Human lecithin: cholesterol acyltransferase deficiency: in vivo kinetics of lowdensity lipoprotein and lipoprotein-X. Arterioscler Thromb Vasc Biol. 2006;26(6):1370-5. (Pubitemid 44305384)
8. Lynn EG, Choy PC, Magil A. O K: uptake and metabolism of lipoprotein-X in mesangial cells. Mol Cell Biochem. 1997;175(1-2):187-94. (Pubitemid 27459876)
9. Rader DJ. Lecithin: cholesterol acyltransferase and atherosclerosis: another high-density lipoprotein story that doesn't quite follow the script. Circulation. 2009;120(7):549-52.
10. Greeve J, Altkemper I, Dieterich JH, Greten H, Windler E. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res. 1993;34(8):1367-83. (Pubitemid 23230314)
11. Paigen B, Ishida BY, Verstuyft J, Winters RB, Albee D. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Arteriosclerosis. 1990;10(2):316-23. (Pubitemid 20103595)
12. Berard AM, Foger B, Remaley A, et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med. 1997;3(7):744-9. (Pubitemid 27298717)
13. Foger B, Chase M, Amar MJ, et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem. 1999;274(52):36912-20.
14. Furbee Jr JW, Parks JS. Transgenic overexpression of human lecithin: cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition. Atherosclerosis. 2002;165(1):89-100. (Pubitemid 35229987)
15. Hoeg JM, Vaisman BL, Demosky Jr SJ, et al. Lecithin: cholesterol acyltransferase overexpression generates hyperalphalipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem. 1996;271(8):4396-402.
16. Brousseau ME, Hoeg JM. Transgenic rabbits as models for atherosclerosis research. J Lipid Res. 1999;40(3):365-75. (Pubitemid 29116139)
17. Brousseau ME, Santamarina-Fojo S, Vaisman BL, et al. Overexpression of human lecithin:cholesterol acyltransferase in cholesterol-fed rabbits: LDL metabolism and HDL metabolism are affected in a gene dose-dependent manner. J Lipid Res. 1997;38(12):2537-47. (Pubitemid 28028138)
18. Sakai N, Vaisman BL, Koch CA, et al. Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT) gene. Generation of a new animal model for human LCAT deficiency. J Biol Chem. 1997;272(11):7506-10. (Pubitemid 27166465)
19. Lambert G, Sakai N, Vaisman BL, et al. Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferasedeficient mice. J Biol Chem. 2001;276(18):15090-8.
20. Ng DS, Maguire GF, Wylie J, et al. Oxidative stress is markedly elevated in lecithin:cholesterol acyltransferase-deficient mice and is paradoxically reversed in the apolipoprotein E knockout background in association with a reduction in atherosclerosis. J Biol Chem. 2002;277(14):11715-20. (Pubitemid 34952725)
21. Furbee Jr JW, Sawyer JK, Parks JS. Lecithin: cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice. J Biol Chem. 2002;277(5):3511-9. (Pubitemid 34953221)
22. Amar MJ, Shamburek RD, Vaisman B, et al. Adenoviral expression of human lecithin-cholesterol acyltransferase in nonhuman primates leads to an antiatherogenic lipoprotein phenotype by increasing high-density lipoprotein and lowering low-density lipoprotein. Metabolism. 2009;58(4):568-75.
23. Zhou M, Sawyer J, Kelley K, et al: Abstract 5920: Lecithin Cholesterol Acyltransferase Promotes Reverse Cholesterol Transport and Attenuates Atherosclerosis Progression in New Zealand White Rabbits. Circulation 2009, 120(18-MeetingAbstracts): S1175-b-.
24. Amar MJ, D'Souza W, Turner S, et al. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Ther. 2010;334(2):634-41.
25. Tanigawa H, Billheimer JT, Tohyama J, et al. Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Circulation. 2009;120(2):160-9.
26. Wang X, Collins HL, Ranalletta M, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007;117(8):2216-24. (Pubitemid 47219566)
27. Sethi AA, Sampson M, Warnick R, et al. High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem. 2010;56 (7):1128-37. This work demonstrates that LCAT and pre-β are good biomarkers for cardiovascular disease.
28. Frohlich J, Dobiasova M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem. 2003;49(11):1873-80. (Pubitemid 37340322)
29. Dullaart RP, Perton F, Sluiter WJ, de Vries R, van Tol A. Plasma lecithin: cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. J Clin Endocrinol Metab. 2008;93(12):4860-6.
30. Dullaart RP, Perton F, Kappelle PJ, de Vries R, Sluiter WJ, van Tol A. Plasma lecithin: cholesterol acyltransferase activity modifies the inverse relationship of C-reactive protein with HDL cholesterol in nondiabetic men. Biochim Biophys Acta. 2010;1801(1):84-8.
31. Hovingh GK, Hutten BA, Holleboom AG, et al. Compromised LCAT function is associated with increased atherosclerosis. Circulation. 2005;112(6):879-84. (Pubitemid 41170075)
32. Holleboom AG, Duivenvoorden R, van den Bogaard B, et al: Carriers of Lcat Gene Mutations Have Increased Atherosclerosis: A 3.0 Tesla Mri Study. Atherosclerosis Supp 2010, 11(2):61-61.
33. Ayyobi AF, McGladdery SH, Chan S, John Mancini GB, Hill JS, Frohlich JJ. Lecithin: cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up. Atherosclerosis. 2004;177(2):361-6. (Pubitemid 39505269)
34. Calabresi L, Baldassarre D, Castelnuovo S, et al. Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation. 2009;120(7):628-35.
35. Wells IC, Peitzmeier G, Vincent JK. Lecithin: cholesterol acyltransferase and lysolecithin in coronary atherosclerosis. Exp Mol Pathol. 1986;45(3):303-10. (Pubitemid 17227291)
36. Rousset X, Vaisman B, Auerbach B, et al: Effect of Recombinant Human Lecithin-cholesterol:acyltransferase Infusion on Lipoprotein Metabolism in Mice. J Pharmacol Exp Ther 2010. This work demonstates the feasibility of LCAT replacement therapy in the case of LCAT deficiency.
37. Brady RO. Enzyme replacement for lysosomal diseases. Annu Rev Med. 2006;57:283-96. (Pubitemid 43261992)
38. Norum KR, Gjone E. The effect of plasma transfusion on the plasma cholesterol esters in patients with familial plasma lecithin: cholesterol acyltransferase deficiency. Scand J Clin Lab Invest. 1968;22(4):339-42.
39. Murayama N, Asano Y, Kato K, et al. Effects of plasma infusion on plasma lipids, apoproteins and plasma enzyme activities in familial lecithin: cholesterol acyltransferase deficiency. Eur J Clin Invest. 1984;14(2):122-9. (Pubitemid 14133891)
40. Klein HG, Santamarina-Fojo S, Duverger N, et al. Fish eye syndrome: a molecular defect in the lecithin-cholesterol acyltransferase (LCAT) gene associated with normal alpha-LCAT-specific activity. Implications for classification and prognosis. The Journal of Clinical Investigation. 1993;92(1):479-85. (Pubitemid 23209032)
41. Asada S, Kuroda M, Aoyagi Y, et al: Disturbed apolipoprotein AI- containing lipoproteins in fish-eye disease are improved by the lecithin:cholesterol acyltransferase produced by gene-transduced adipocytes in vitro. Molecular Genetics and Metabolism, In Press.
42. Kuroda M, Aoyagi Y, Asada S, et al: Ceiling culture-derived proliferative adipocytes are a possible delivery vehicle for enzyme replacement therapy in lecithin:cholesterol acyltransferase deficiency. Gene Ther Mol Biol. In press. This article presents an alternative to LCAT injections for a treatment of the human LCAT deficiency.
43. Remaley AT, Amar M, Sviridov D. HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Rev Cardiovasc Ther. 2008;6(9):1203-15.
44. Sethi AA, Amar M, Shamburek RD, Remaley AT. Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Curr Opin Investig Drugs. 2007;8(3):201-12. (Pubitemid 46438455)
45. Yvan-Charvet L, Pagler T, Gautier EL, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. 2010;328(5986):1689-93. This article presents new data on the interaction of HDL metabolism and blood cells.
46. Tardif JC, Heinonen T, Noble S. High-density lipoprotein/apolipoprotein A-I infusion therapy. Curr Atheroscler Rep. 2009;11(1):58-63.
47. Feister HA, Auerbach BJ, Cole LA, Krause BR, Karathanasis SK. Identification of an IL-6 response element in the human LCAT promoter. Journal of Lipid Research. 2002;43(6):960-70. (Pubitemid 34602619)
48. Zhou M, Fordstrom P, Zhang J, et al. Novel small molecule LCAT activators raise HDL levels in rodent models. Arterioscl Throm Vas. 2008;28(6):E65-6.
49. Vaisman BL, Klein HG, Rouis M, et al. Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J Biol Chem. 1995;270(20):12269-75.
50. Mehlum A, Staels B, Duverger N, et al. Tissue-specific expression of the human gene for lecithin: cholesterol acyltransferase in transgenic mice alters blood lipids, lipoproteins and lipases towards a less atherogenic profile. Eur J Biochem. 1995;230(2):567-75.
51. Van Craeyveld E, Lievens J, Jacobs F, Feng Y, Snoeys J, De Geest B. Apolipoprotein A-I and lecithin: cholesterol acyltransferase transfer induce cholesterol unloading in complex atherosclerotic lesions. Gene Ther. 2009;16(6):757-65.